|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- Special Health Authorities
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- DHSC Supply Disruption - Medicines
|
| Title: |
|
Remdesivir for patients hospitalised due to COVID-19 (adults and adolescents 12 years and older)
|
| Broadcast content: |
|
***05/05/2022 - An updated Clinical guide has been attached following publication.***
The
published policy has been updated to reflect the latest available information
on the use of remdesivir in patients admitted to hospital due to COVID-19. A graphical clinical guide (attached below), summarising the
main COVID treatment options available to this patient cohort, is also provided
to support clinical decision making. The
updated policy provides links to the two other published clinical access policies
supporting the use of remdesivir in patients
with hospital-onset COVID infection, and non-hospitalised
patients at highest risk from COVID infection, respectively.
|
| Additional information: |
|
This alert does not need to be cascaded to Primary Care
|